Skip directly to site content Skip directly to page options Skip directly to A-Z link


Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People
															Search
		×
			NIOSH
			NIOSH
				All CDC
				Submit
			For a full list of topics:A-Z Index
			Advanced Search
		Advanced Search


The National Institute for Occupational Safety and Health (NIOSH)


Facebook
        Twitter
        LinkedIn
        Syndicate





Current Intelligence Bulletin 26: Niax® Catalyst ESN.... A Mixture of Dimethylamino -propionitrile and Bis(2-[dimethylamino)ethyl] ether										Related Pages
										May 22, 1978
DHHS (NIOSH) Publication Number 78-157
**Note:** The respirator recommendations in this document have been updated. Please refer to the NIOSH Pocket Guide (NPG) to Chemical Hazards for the current recommendations.

Identifiers and Synonyms for Dimethylaminopropionitrile
Chemical Abstracts Service Registry Number 1738-25-6
NIOSH RTECS Number UG15750
Chemical Formula C5H10N2
3-(Dimethylamino)propanenitrile
3-(Dimethylamino)propionitrile
β-(Dimethylamino)propionitrile
N,N-Dimethylamino-3-propionitrile
3-(N,N-Dimethylamino)propionitrile
β-N-Dimethylaminopropionitrile

Identifiers and Synonyms for Bis[2-(Dimethylamino)Ethyl] Ether
Chemical Abstracts Service Registry Number 3033-62-3
NIOSH RTECS Number KR94600
Chemical Formula C8H20N2O
A99
A99 amine
Bis 2-(dimethylamino)ethyl)ether
Kalpur PC
NIAX A99
2,2′-Oxybis(N,N-dimethylethanamine)
2,2’Oxybis(N,N-dimethylethylamine)

Joint NIOSH/OSHA Current Intelligence Bulletin:NIAX® Catalyst ESN
A Mixture of Dimethylaminopropionitrile and Bis[2-(dimethylamino)ethyl] ether
The National Institute for Occupational Safety and Health (NIOSH) and the Occupational Safety and Health Administration (OSHA) jointly recommend that NIAX® Catalyst ESN and, its components, dimethylaminopropionitrile and bis[2-(dimethylamino)ethyl] ether, as well as formulations containing either component, be handled in the workplace as exceedingly hazardous materials. Investigations of outbreaks of urinary dysfunction among workers at a number of facilities that manufacture flexible polyurethane foam strongly suggest an association between NIAX® Catalyst ESN and the urological disorders. There is no current Federal standard for occupational exposure to NIAX® Catalyst ESN or either of its components. However, on April 7, 1978, OSHA issued a Health Hazard Alert and indicated “it is imperative that worker exposure to ESN and its components be completely avoided.”

Background
NIAX® Catalyst ESN, a proprietary product of Union Carbide Corporation, is composed of dimethylaminopropionitrile (95%) and bis[2-(dimethyl-amino)ethyl] ether (5%). Similar mixtures were also marketed as NIAX® Catalysts 125 and 126. These catalysts were used in the manufacture of flexible polyurethane foams and may comprise from 0.5% to 2% of the wet urethane liquid prior to foaming. Union Carbide has voluntarily discontinued the sale of these three catalysts as well as dimethylaminopropionitrile.
Dimethylaminopropionitrile is also used as a component of acrylamide based gels (for soil grouting and other purposes), and as an intermediate in the synthesis of dimethylaminopropylamine and some pharmaceuticals. Manufacturers of dimethylaminopropionitrile include Abbott Laboratories, American Cyanamid Company, Jefferson Chemical Company, and Union Carbide Corporation.
Bis[2-(dimethylamino)ethyl] ether is manufactured in the United States exclusively by Union Carbide and used extensively in their line of catalysts for flexible polyurethane foams. Bis[2-(dimethylamino)ethyl] ether may comprise from O.O2% to 0.1% of the wet urethane liquid prior to foaming. NIOSH and OSHA are unaware of any other application of bis[2-(dimethylamino)ethyl] ether.

Human Toxicity
Preliminary results of NIOSH Health Hazard Evaluations suggest NIAX® Catalyst ESN is neurotoxic, producing urinary bladder dysfunction as the prevailing clinical feature.
Of the ten industrial facilities reported to have used commercial quantities of NIAX® Catalyst ESN, five are known to have had excessive numbers of their workers seek medical attention for urological and/or neurological, problems. Common urinary tract symptoms after exposure include difficulty beginning urination, inadequate bladder emptying, strain on urination, increased duration of voiding time, and post void fullness. Other symptoms include frequent urination, pain and burning on urination, as well as impotence. Neurological manifestations include dysesthesias in the form of pins and needles sensation in the hands and feet. Muscular weakness, lassitude, nausea, and vomiting were also reported. Exposure may occur by inhalation, skin absorption, and ingestion.
NIOSH epidemiological and medical studies are presently underway in two of the industrial facilities involved. Clinical manifestations in exposed workers coincide with the introduction or increased use of the catalyst in manufacturing processes. After exposure is discontinued, improvement occurs in some individuals over a variable period of time. NIOSH is investigating whether symptoms persist after exposure to the catalyst is eliminated.
Approximately a third of the hundred workers exposed at one plant and half of the two hundred exposed workers at the other plant studied reported urinary problems. Detailed clinical and laboratory studies of eight workers severely affected with urinary problems revealed that five of the eight did not have a bladder reflex and were therefore unaware of the need to void as their bladders became full. Though not conclusive, the evidence suggests that the absent bladder reflex may be the cause of urinary retention and abnormal change in bladder habits. Long term urinary retention can lead to urinary tract infection and kidney damage, and thus can pose a threat to life. In addition to bladder dysfunction, some of the workers were found to have decreased nerve conduction times of the lower legs.
Sufficient evidence does exist to suggest that occupational exposure to NIAX® Catalyst ESN is associated with the urinary and neurologic abnormalities. The extent of toxicity of the catalyst to other systems and organs including kidney, liver, eye and skin are unknown. Definitive information regarding safe levels of exposure to NIAX® Catalyst ESN or its components is not available at this time.

Animal Studies
Dr. Alan Pestronk (The Johns Hopkins University) is currently investigating the effect of NIAX® Catalyst ESN, as well as its components, on the nervous system of laboratory rats. Results of this study are not yet available. Several propionitriles have been previously reported to be neurotoxins, however, specific data regarding the neurotoxicity of dimethylaminopropionitrile could not be located. Union Carbide is also sponsoring toxicity studies of NIAX® Catalyst ESN, dimethylaminopropionitrile and bis[2-(dimethylamino)ethyl] ether; these studies have been in progress for approximately two weeks but have not proceeded far enough to be adequately evaluated.

Conclusions
Although there does appear to be an association between NIAX® Catalyst ESN and the outbreaks of urinary dysfunction, it is not now known whether either component of the mixture could cause the disorder itself. Additional research in this area is clearly appropriate. Union Carbide has suggested that the nitrile component (dimethylaminopropionitrile) may be the causative agent. They stated that bis[2-(dimethylamino)ethyl] ether has been used in urethane catalyst systems for fifteen years and proper use of the material has not been known to cause any adverse health effects. (Acute overexposure may result in symptoms characteristic of amine toxicity).

Recommendation
The National Institute for Occupational Safety and Health (NIOSH) and the Occupational Safety and Health Administration (OSHA) jointly recommend that occupational exposure to NIAX® Catalyst ESN its components, dimethylaminopropionitrile and bis[2-(dimethylamino)ethyl] ether, as well as formulations containing either component, be minimized. Exposures should be limited to as few employees as possible, while minimizing workplace exposure levels with engineering and work practice controls. Exposed employees should be carefully monitored for potential disorders of the nervous and genitourinary system. Although substitution is a possible control measure, alternatives to NIAX® Catalyst ESN or its components should be fully evaluated with regard to possible adverse health effects.
*[signature]*
Eula Bingham, Ph.D.
Assistant Secretary of Labor
Occupational Safety and Health Administration
*[signature]*
J. Donald Millar, M.D.
Asistant Surgeon General
Acting Director
National Institute for Occupational Safety and Health

Suggested Guidelines for Minimizing Employee Exposure to
NIAX® CATALYST ESN and its Components, Dimethylaminopropionitrile and bis[2-(dimethylamino)ethyl] ether
NIOSH and OSHA recommend that it would be prudent to handle NIAX® Catalyst ESN and its components in the workplace as exceedingly hazardous materials. Workplace exposure levels and employee exposure should be minimized. The area in which NIAX® Catalyst ESN, or either of its components, is used should be restricted to only those employees essential to the process or operation.

Exposure Monitoring
Initial and routine employee exposure surveys should be made by competent industrial hygiene and engineering personnel. These surveys are necessary to determine the extent of employee exposure and to ensure that controls are effective. The sampling and analytical method recommended by the Union Carbide Corporation for the bis-ether component of NIAX® Catalyst ESN is currently being used and evaluated by NIOSH as a procedure for the analysis of dimethylaminopropionitrile as well as bis[2-(dimethylamino)ethyl] ether.
The *NIOSH Occupational Exposure Sampling Strategy Manual,* NIOSH Publication #77-173, may be helpful in developing efficient programs to monitor employee exposures to NIAX® Catalyst ESN and its components. The manual discusses determination of the need for exposure measurements, selection of appropriate employees for exposure evaluation, and selection of sampling times.
Employee exposure measurements should consist of 8-hour TWA (time-weighted average) exposure estimates calculated from personal or breathing zone samples (air that would most nearly represent that inhaled by the employees). Area and source measurements may be useful to determine problem areas, processes, and operations.

Minimizing Employee Exposure
There are four basic methods of limiting employee exposure to NIAX® Catalyst ESN and its components. None of these is a simple industrial hygiene or management decision and careful planning and thought should be used prior to implementation of any of these.
Product Substitution
One method is the substitution of an alternative material with a lower potential health risk. However, extreme care must be used when selecting possible substitutes. Alternatives to NIAX® Catalyst ESN and its components should be fully evaluated with regard to possible human effects. Unless the toxic effects of the alternative have been thoroughly evaluated, a seemingly safe replacement may be found to induce serious health effects, possibly only after years of use.
Contaminant Controls
The most effective control of NIAX® Catalyst ESN and its components is by local exhaust ventilation and/or enclosure of the operation at the source of contamination.
If feasible, the process or operation should be enclosed with a slight vacuum so that any leakage will result in the flow of air into the enclosure.
The next most effective means of control is a well designed local exhaust ventilation system that physically encloses the process as much as possible, with sufficient capture velocity to keep the contaminant from entering the work atmosphere.
To ensure that ventilation equipment is working effectively, air velocity, static pressure, or air volume should be checked every three months. System effectiveness should be checked soon after any change in production, process, or control which might result in significant increases in airborne exposures to NIAX® Catalyst ESN or its components.
In cases where the contaminant release is not excessive and is not in the workers’ breathing area, good general dilution ventilation may assist in keeping the contaminant levels from reaching hazardous levels.
Care should be exercised in controlling exposure resulting from residual material in off-gassing from the uncured or curing products.
Employee Isolation
A third alternative is the isolation of employees. It frequently involves the use of automated equipment operated by personnel observing from a closed control booth or room. The control room is maintained at a greater air pressure than that surrounding the process equipment so that air flow is out of, rather than into, the room. This type of control will not protect those employees who must do process checks, adjustments, maintenance, and related operations.
Personal Protective Equipment
The least desirable way to control employee exposures is with the use of personal protective equipment, which may include respirators, gloves, goggles, etc. This equipment should not be used as the only means to prevent or minimize exposure during routine operations.
Exposure to NIAX® Catalyst ESN or its components should not be controlled with the use of respirators except:
During the time period necessary to install or implement engineering or work practice controls; or
In work situations in which engineering and work practice controls are technically not feasible; or
For maintenance; or
For operations which require entry into tanks or closed vessels; or
In emergencies.Neither NIOSH or OSHA has definitive information concerning the warning properties of NIAX® Catalyst ESN or its components or the service lives of typical industrial respirator for these substances. Therefore, as an interim recommendation, NIOSH and OSHA feel that only the following type respirators may be used for personal respiratory protection against NIAX® Catalyst ESN or its components as allowed under the previous guidelines.
A type C supplied-air respirator with a full facepiece operated in pressure-demand or other positive pressure mode or with a full facepiece, hood, or helmet operated in continuous-flow mode.
Self-contained breathing apparatus with a full facepiece operated in pressure-demand or other positive pressure mode.
A combination respirator which includes a type C supplied-air respirator with a full facepiece operated in pressure-demand mode or other positive pressure or continuous-flow mode and an auxiliary self-contained breathing apparatus operated in pressure-demand or positive pressure mode.
Only respirators approved by the National Institute for Occupational Safety and Health (NIOSH) should be used. Refer to *NIOSH Certified Equipment, December 15, 1975,* NIOSH publication #76-145 and *Cumulative Supplement June 1977, NIOSH Certified Equipment,* NIOSH publication #77-195. The use of faceseal coverlets or socks with any respirator voids NIOSH approvals.
Refer to *A Guide to Industrial Respiratory Protection,* NIOSH publication #76-189 for guidelines on appropriate respiratory protection programs.
Proper maintenance procedures and good housekeeping in the work area are very important aspects of a good control program. In addition, it is vital that employees be educated as to the nature and control of the hazard, and proper personal hygiene.
							
					
						Page last reviewed:  June 6, 2014					Content source: 	National Institute for Occupational Safety and Health homeNIOSH Publications & Products
NIOSH-Issued Publications
Search NIOSHTIC-2 Research Database
Docket
Documents for Public Review
Peer Review Agenda
Databases
eNews
Federal Register Noticesplus icon
FRN Archive 2007-2010
FRN Archive 2005-2006
FRN Archive 2001-2004
FRN Archive 1996-2000
Press Releases and Updatesplus icon
Press Release Archives 2010-2013
Press Release Archives 2006-2009
Press Release Archives 2001-2005
Press Release Archives 1998-2000
Press Release Archives 1992-1997
Regulations
Regulatory Agenda
Science Blog
Software
Video Follow NIOSH Facebook
Pinterest
Twitter
YouTube
 NIOSH Homepage NIOSH A-Z
Workplace Safety & Health Topics
Publications and Products
Programs
Contact NIOSH


About CDC
					Contact Us
					800-232-4636
 Facebook Twitter Instagram LinkedIn Youtube Pinterest Snapchat
 CONTACT CDC
				Contact Us
							Call 800-232-4636
							Email Us
			ABOUT CDC
				About CDC
							Jobs
							Funding
			POLICIES
				Accessibility
							External Links
							Privacy
							Policies
							No Fear Act
							FOIA
							OIG
							Nondiscrimination
							Vulnerability Disclosure Policy
			CONNECT WITH US
				Facebook
								Twitter
								Instagram
								LinkedIn
							Youtube
								Pinterest
								Snapchat
								Email
			LANGUAGES
				Español
							繁體中文
							Tiếng Việt
							한국어
							Tagalog
							Русский
							العربية
							Kreyòl Ayisyen
							Français
							Polski
							Português
							Italiano
							Deutsch
							日本語
							فارسی
							English


U.S. Department of Health & Human Services
			Accessibility
			External Links
			Privacy
			Policies
			No Fear Act
			FOIA
			Nondiscrimination
			OIG
			Vulnerability Disclosure Policy
			USA.gov


Exit Notification / Disclaimer Policy Close
 Links with this icon  indicate that you are leaving the CDC website. The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
				Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
				You will be subject to the destination website's privacy policy when you follow the link.
				CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website. Website Disclaimers
 Cancel Continue